Hussman Strategic Advisors Inc. Invests $1.99 Million in Astrana Health, Inc. (NASDAQ:ASTH)

Hussman Strategic Advisors Inc. purchased a new stake in shares of Astrana Health, Inc. (NASDAQ:ASTH) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 63,000 shares of the company’s stock, valued at approximately $1,986,000.

Several other institutional investors have also recently added to or reduced their stakes in ASTH. Nisa Investment Advisors LLC bought a new position in Astrana Health during the 3rd quarter valued at about $35,000. KBC Group NV bought a new position in Astrana Health during the 3rd quarter valued at about $70,000. Quarry LP bought a new position in Astrana Health during the 3rd quarter valued at about $77,000. Quest Partners LLC bought a new position in Astrana Health during the 3rd quarter valued at about $133,000. Finally, Paloma Partners Management Co bought a new position in Astrana Health during the 3rd quarter valued at about $220,000. 52.77% of the stock is owned by institutional investors.

Astrana Health Trading Up 0.6 %

ASTH opened at $39.13 on Thursday. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $2.20 billion, a PE ratio of 30.10, a PEG ratio of 1.50 and a beta of 1.20. Astrana Health, Inc. has a 1-year low of $29.08 and a 1-year high of $63.20. The firm has a 50-day moving average price of $35.11 and a two-hundred day moving average price of $45.12.

Analyst Ratings Changes

Several brokerages recently issued reports on ASTH. Truist Financial cut their price target on shares of Astrana Health from $59.00 to $50.00 and set a “buy” rating for the company in a report on Monday, January 13th. Macquarie upgraded shares of Astrana Health to a “hold” rating in a research report on Monday, December 16th. Finally, Robert W. Baird raised their price objective on shares of Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Astrana Health currently has an average rating of “Moderate Buy” and an average price target of $63.67.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.